Nevertheless, the current RCC treatment strategies mainly include the use of immune checkpoint inhibitors (ICIs) in combination with treatment modalities.[7] In RCC patients at an advanced stage, tyrosine kinase inhibitors (TKIs) synergistically increase the efficacy of treatment with programmed death (PD) 1/PD ligand 1 (PD-L1) monoclonal antibody. Here, CD274 is linked to renal cell carcinoma.